These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

675 related articles for article (PubMed ID: 26420854)

  • 21. Comparison of HPV DNA vaccines employing intracellular targeting strategies.
    Kim JW; Hung CF; Juang J; He L; Kim TW; Armstrong DK; Pai SI; Chen PJ; Lin CT; Boyd DA; Wu TC
    Gene Ther; 2004 Jun; 11(12):1011-8. PubMed ID: 14985791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
    Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
    Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
    Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
    Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses.
    Çuburu N; Graham BS; Buck CB; Kines RC; Pang YY; Day PM; Lowy DR; Schiller JT
    J Clin Invest; 2012 Dec; 122(12):4606-20. PubMed ID: 23143305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel self-assembled nanoparticle vaccine with HIV-1 Tat₄₉₋₅₇/HPV16 E7₄₉₋₅₇ fusion peptide and GM-CSF DNA elicits potent and prolonged CD8⁺ T cell-dependent anti-tumor immunity in mice.
    Tang J; Yin R; Tian Y; Huang Z; Shi J; Fu X; Wang L; Wu Y; Hao F; Ni B
    Vaccine; 2012 Feb; 30(6):1071-82. PubMed ID: 22178528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells.
    Choi YW; Kang MC; Seo YB; Namkoong H; Park Y; Choi DH; Suh YS; Lee SW; Sung YC; Jin HT
    Clin Cancer Res; 2016 Dec; 22(23):5898-5908. PubMed ID: 27407095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HSP70 modified response against HPV based tumor.
    Farzanehpour M; Soleimanjahi H; Hassan ZM; Amanzadeh A; Ghaemi A; Fazeli M
    Eur Rev Med Pharmacol Sci; 2013 Jan; 17(2):228-34. PubMed ID: 23377813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model.
    Peng S; Tan M; Li YD; Cheng MA; Farmer E; Ferrall L; Gaillard S; Roden RBS; Hung CF; Wu TC
    Cancer Immunol Immunother; 2021 Apr; 70(4):1049-1062. PubMed ID: 33108473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3).
    Alvarez RD; Huh WK; Bae S; Lamb LS; Conner MG; Boyer J; Wang C; Hung CF; Sauter E; Paradis M; Adams EA; Hester S; Jackson BE; Wu TC; Trimble CL
    Gynecol Oncol; 2016 Feb; 140(2):245-52. PubMed ID: 26616223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA vaccines employing intracellular targeting strategies and a strategy to prolong dendritic cell life generate a higher number of CD8+ memory T cells and better long-term antitumor effects compared with a DNA prime-vaccinia boost regimen.
    Kim TW; Lee JH; He L; Boyd DA; Hung CF; Wu TC
    Hum Gene Ther; 2005 Jan; 16(1):26-34. PubMed ID: 15703486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice.
    Domingos-Pereira S; Decrausaz L; Derré L; Bobst M; Romero P; Schiller JT; Jichlinski P; Nardelli-Haefliger D
    Mucosal Immunol; 2013 Mar; 6(2):393-404. PubMed ID: 22968420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Genetically Modified attenuated
    Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
    Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
    Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
    Kaufmann AM; Stern PL; Rankin EM; Sommer H; Nuessler V; Schneider A; Adams M; Onon TS; Bauknecht T; Wagner U; Kroon K; Hickling J; Boswell CM; Stacey SN; Kitchener HC; Gillard J; Wanders J; Roberts JS; Zwierzina H
    Clin Cancer Res; 2002 Dec; 8(12):3676-85. PubMed ID: 12473576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
    Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ
    J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.
    Karanam B; Gambhira R; Peng S; Jagu S; Kim DJ; Ketner GW; Stern PL; Adams RJ; Roden RB
    Vaccine; 2009 Feb; 27(7):1040-9. PubMed ID: 19095032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts.
    Tseng CW; Trimble C; Zeng Q; Monie A; Alvarez RD; Huh WK; Hoory T; Wang MC; Hung CF; Wu TC
    Cancer Immunol Immunother; 2009 May; 58(5):737-48. PubMed ID: 18815785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
    Wick DA; Webb JR
    Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced therapeutic effects conferred by an experimental DNA vaccine targeting human papillomavirus-induced tumors.
    Diniz MO; Cariri FA; Aps LR; Ferreira LC
    Hum Gene Ther; 2013 Oct; 24(10):861-70. PubMed ID: 24007495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Herpes Simplex Virus Glycoprotein D Targets a Specific Dendritic Cell Subset and Improves the Performance of Vaccines to Human Papillomavirus-Associated Tumors.
    Porchia BFMM; Moreno ACR; Ramos RN; Diniz MO; de Andrade LHTM; Rosa DS; Barbuto JAM; Boscardin SB; Ferreira LCS
    Mol Cancer Ther; 2017 Sep; 16(9):1922-1933. PubMed ID: 28522585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.